Novo Nordisk localizes production in the Kaluga Region


09 July 2021
https://investkaluga.com

Novo Nordisk is at the first phase of localization of new generation insulin at its facility in the Kaluga Region.

45.7 mln
Jobs: 155
Kaluga region

Investor profile

Novo Nordisk A/S

Denmark

Company's website: www.novonordisk.com

T: +45 4444 8888

Public company (NVO)

E-mail: dabo@novonordisk.com

Contact: Lars Rebien Sørensen, CEO

The world’s biggest insulin maker.